1 citations · 2 across the 3 of their papers we have counts for
4 papers · 1 filter
PKComb-BOIN12: A Pharmacokinetically Guided Bayesian Design for Dose Optimisation in Oncology Drug-Combination Trials
Jieqi Tu, Ruitao Lin, Ayon Mukherjee
Dose optimisation of two-agent combinations in early-phase oncology trials must jointly balance toxicity, efficacy, and pharmacologically meaningful drug exposure, yet existing mod…
TITE-STEIN: Time-to-event Simple Toxicity and Efficacy Interval Design to Accelerate Phase I/II Trials
Hao Sun, Jieqi Tu, Revathi Ananthakrishnan +1
Oncology dose-finding trials are shifting from identifying the maximum tolerated dose (MTD) to determining the optimal biological dose (OBD), driven by the need for efficient metho…
Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology
Hao Sun, Hsin-Yu Lin, Jieqi Tu +2
Traditional phase I dose finding cancer clinical trial designs aim to determine the maximum tolerated dose (MTD) of the investigational cytotoxic agent based on a single toxicity o…
PKBOIN-12: A Bayesian optimal interval Phase I/II design incorporating pharmacokinetics outcomes to find the optimal biological dose
Hao Sun, Jieqi Tu
Immunotherapies and targeted therapies have gained popularity due to their promising therapeutic effects across multiple treatment areas. The focus of early phase dose-finding clin…